Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2003 2
2004 1
2005 1
2007 2
2008 3
2009 3
2010 1
2011 4
2012 6
2013 7
2014 5
2015 9
2016 4
2017 11
2018 7
2019 11
2020 8
2021 14
2022 12
2023 9
2024 13
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.
Klomp JE, Diehl JN, Klomp JA, Edwards AC, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A, Johnson JL, Huntsman EM, Yaron TM, Pierobon M, Baldelli E, Prevatte AW, Barker NK, Herring LE, Petricoin EF 3rd, Graves LM, Cantley LC, Cox AD, Der CJ, Stalnecker CA. Klomp JE, et al. Among authors: pierobon m. Science. 2024 Jun 7;384(6700):eadk0850. doi: 10.1126/science.adk0850. Epub 2024 Jun 7. Science. 2024. PMID: 38843329 Free PMC article.
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG. Hallin J, et al. Among authors: pierobon m. Cancer Discov. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28. Cancer Discov. 2020. PMID: 31658955 Free PMC article.
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM, Ozkan-Dagliyan I, Baldelli E, Calvert V, Pierobon M, Sorrentino JA, Beelen AP, Bublitz N, Lüthen M, Wood KC, Petricoin EF, Sers C, McRee AJ, Cox AD, Der CJ. Goodwin CM, et al. Among authors: pierobon m. Cancer Res. 2023 Jan 4;83(1):141-157. doi: 10.1158/0008-5472.CAN-22-0391. Cancer Res. 2023. PMID: 36346366 Free PMC article. Clinical Trial.
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Bryant KL, et al. Among authors: pierobon m. Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833752 Free PMC article.
Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.
Soltis AR, Bateman NW, Liu J, Nguyen T, Franks TJ, Zhang X, Dalgard CL, Viollet C, Somiari S, Yan C, Zeman K, Skinner WJ, Lee JSH, Pollard HB, Turner C, Petricoin EF, Meerzaman D, Conrads TP, Hu H; APOLLO Research Network; Shriver CD, Moskaluk CA, Browning RF Jr, Wilkerson MD. Soltis AR, et al. Cell Rep Med. 2022 Nov 15;3(11):100819. doi: 10.1016/j.xcrm.2022.100819. Cell Rep Med. 2022. PMID: 36384096 Free PMC article.
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.
Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge AG, Stachler MD, Liao J, Zhou J, Wu Z, Akarca FG, de Klerk LK, Derks S, Pierobon M, Hoadley KA, Wang TC, Church G, Wong KK, Petricoin EF, Cox AD, Lowy DR, Der CJ, Bass AJ. Zhang H, et al. Among authors: pierobon m. Cancer Discov. 2020 Feb;10(2):288-305. doi: 10.1158/2159-8290.CD-19-0811. Epub 2019 Nov 26. Cancer Discov. 2020. PMID: 31771969 Free PMC article.
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.
Lin KH, Rutter JC, Xie A, Killarney ST, Vaganay C, Benaksas C, Ling F, Sodaro G, Meslin PA, Bassil CF, Fenouille N, Hoj J, Washart R, Ang HX, Cerda-Smith C, Chaintreuil P, Jacquel A, Auberger P, Forget A, Itzykson R, Lu M, Lin J, Pierobon M, Sheng Z, Li X, Chilkoti A, Owzar K, Rizzieri DA, Pardee TS, Benajiba L, Petricoin E, Puissant A, Wood KC. Lin KH, et al. Among authors: pierobon m. Nat Cancer. 2022 Jul;3(7):837-851. doi: 10.1038/s43018-022-00394-x. Epub 2022 Jun 6. Nat Cancer. 2022. PMID: 35668193 Free PMC article.
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.
Drizyte-Miller K, Engstrom LD, Klomp JA, Stalnecker CA, Stamey AG, Taylor KE, Roach MK, Robb R, Waters LM, Calinisan A, Degan S, Chang WH, Helu XM, Nguyen D, Baldelli E, Pierobon M, Petricoin EF, Briere DM, Hallin J, Christensen JG, Bryant KL, Cox AD, Olson P, Der CJ. Drizyte-Miller K, et al. Among authors: pierobon m. Cancer Res. 2025 Sep 15;85(18):3540-3557. doi: 10.1158/0008-5472.CAN-25-1507. Cancer Res. 2025. PMID: 40694535
Impact of a two step antimicrobial stewardship program in a paediatric haematology and oncology unit.
Liberati C, Barbieri E, Cavagnero F, Petris MG, Brigadoi G, Reggiani G, De Pieri M, Pierobon M, Marzollo A, Gabelli M, Trivellato S, Rigotti E, Opri F, Mengato D, Venturini F, De Canale E, Del Vecchio C, Giaquinto C, Carrara E, Tacconelli E, Biffi A, Donà D. Liberati C, et al. Among authors: pierobon m. Sci Rep. 2024 Nov 26;14(1):29296. doi: 10.1038/s41598-024-80163-1. Sci Rep. 2024. PMID: 39592720 Free PMC article.
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, Der CJ. Klomp JE, et al. Among authors: pierobon m. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060. Cell Rep. 2021. PMID: 34852220 Free PMC article.
127 results